471 patents
Page 13 of 24
Utility
Combinations for Treating Cancer
18 Nov 21
Provided herein are methods and combinations for treating a subject having cancer by administering to the subject a PD-1/PD-L1 axis inhibitor, a CD-122-biased-cytokine agonist, and optionally a PARP inhibitor.
Christoffel Hendrik Boshoff, Rossano Cesari, Cristian Massacesi, Deborah Charych
Filed: 4 Nov 19
Utility
Combinations of Tgf-beta Inhibitors and CDK Inhibitors for Cancer Treatments
11 Nov 21
This invention relates to a method of treating breast cancer by administering a TGFβ inhibitor in combination with a CDK inhibitor to a patient in need therof.
Flavia Mercer PERNASETTI
Filed: 16 Sep 19
Utility
GLP-1 Receptor Agonists and Uses Thereof
28 Oct 21
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Gary Erik Aspnes, Scott W. Bagley, Edward L. Conn, John M. Curto, David J. Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
Filed: 13 Jun 19
Utility
IL-15 Variants and Uses Thereof
21 Oct 21
The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof.
Yik Andy Yeung, Reid Martin Renny Feldman, Ling Hon Matthew Chu, Javier Fernando Chaparro Riggers, Ivana Djuretic, Laura Lin, Lidia Mosyak
Filed: 24 Jun 21
Utility
Dosage Regimen For MAdCAM Antagonists
21 Oct 21
The present invention provides a method for the treatment of a patient comprising administering to the patient an initial dose of between about 1 mg and about 150 mg of a MAdCAM antagonist antibody.
Fabio CATALDI, Robert A. CLARE, Gail M. COMER, Vivekananda PRADHAN, Alaa AHMAD, Mina HASSAN-ZAHRAEE, Mera Krishnan TILLEY, Weidong ZHANG, Anindita BANERJEE, Karen Michelle PAGE, Michael Steven VINCENT, David J. VON SCHACK
Filed: 30 Nov 20
Utility
Solid Dosage Forms of Palbociclib
14 Oct 21
The present invention relates to solid dosage forms of palbociclib comprising a water-soluble acid.
Fady Makram Louiz Ibrahim, Matthew Patrick Mullarney, Ravi M. Shanker, Barbara Rodriguez Spong, Jian Wang
Filed: 17 Jun 21
Utility
Heteroaryl Sulfone-based Conjugation Handles, Methods for Their Preparation, and Their Use In Synthesizing Antibody Drug Conjugates
7 Oct 21
Russell George DUSHIN, Daniel P. UCCELLO, Jeremy STARR, Ye CHE, Mark FLANAGAN, Jeffrey M. CASAVANT, Christopher John O'DONNELL, Gary Frederick FILZEN, Jennifer YOUNG, Joseph A. ABRAMITE, Lawrence N. TUMEY, Ludivine MOINE, Adam Matthew GILBERT, Lee R. ROBERTS
Filed: 31 Jul 17
Utility
Substituted 3-AZABICYCLO[3.1.0]HEXANES As Ketohexokinase Inhibitors
7 Oct 21
Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
Filed: 23 Mar 21
Utility
Diacylglycerol Acyl Transferase 2 Inhibitors
7 Oct 21
Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
Filed: 11 Jun 21
Utility
Heterocyclic Spiro Compounds As MAGL Inhibitors
7 Oct 21
Michael Aaron Brodney, Christopher Ryan Butler, Laura Ann McAllister, Steven Victor O'Neil
Filed: 10 Jul 19
Utility
5,7-DIHYDRO-PYRROLO-PYRIDINE Derivatives
7 Oct 21
Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Laura Ann McAllister, Erik Alphie LaChapelle, Adam Matthew Gilbert
Filed: 1 Jun 21
Utility
Soluble Fibroblast Growth Factor Receptor 3 (SFGFR3) Polypeptides and Uses Thereof
7 Oct 21
The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides.
Elvire Gouze, Stéphanie Garcia
Filed: 20 Apr 21
Utility
Heteroaromatic Compounds and Their Use As Dopamine D1 Ligands
30 Sep 21
Michael Aaron Brodney, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green, Jaclyn Louise Henderson, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Lei Zhang
Filed: 17 Mar 21
Utility
CorrectedQuinazoline Analogs As Receptor Tyrosine Kinase Inhibitors
16 Sep 21
The invention includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
Filed: 31 Jan 19
Utility
Process for Preparing Pneumococcal Polysaccharide-protein Conjugates
16 Sep 21
An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described.
William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
Filed: 24 May 21
Utility
Liquid Bendamustine Pharmaceutical Compositions
9 Sep 21
Concentrated liquid pharmaceutical compositions comprising a) a pharmaceutically effective amount of bendamustine or a pharmaceutically acceptable salt thereof, b) a non-aqueous solvent, and c) at least about 2% water, suitable, after dilution, for administration to a mammal by injection are provided.
Andrew Malcolm Knill, Noel Norris
Filed: 14 Aug 19
Utility
Pharmaceutical Aqueous Formulation Comprising 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA
2 Sep 21
The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable alkanesulphonate salt thereof, that is a clear solution.
James Joseph Hussey, Andrew Gilbert Bright
Filed: 20 Aug 18
Utility
Escherichia Coli Compositions and Methods Thereof
2 Sep 21
This invention provides a polypeptide derived from E. coli or a fragment thereof, including compositions and methods thereof.
Robert G.K. Donald, Rosalind Pan
Filed: 22 Feb 21
Utility
Solid State Forms of (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE and Uses Thereof
2 Sep 21
The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Elaine GREER, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
Filed: 19 Feb 21
Utility
CDK2 Inhibitors
2 Sep 21
Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton
Filed: 20 Apr 21